跳至主要内容

博文

目前显示的是标签为“TQB2450”的博文

正大天晴国内开启两项TQB2450联合安罗替尼用于非小细胞肺癌临床Ib期研究

今日正大天晴公示最新临床研究 PD-L1抑制剂联合VEGFR抑制剂 (即TQB2450联合安罗替尼) 用于治疗NSCLC的Ib期临床研究
NCT03910127

另外
同时开启的还有二者联合
用于晚期突变阳性的非小细胞肺癌
临床Ib期研究
NCT03910270

目前TQB2450已开启多个临床研究 包括NSCLC/TNBC/NSCLC/HCC等适应症 如下所示

NCT03910127
Study Design Go to   Study Type  :Interventional  (Clinical Trial)Estimated Enrollment  :90 participantsAllocation:RandomizedIntervention Model:Parallel AssignmentMasking:Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose:TreatmentOfficial Title:A Phase Ib, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Efficacy and Safety of TQB2450 Combined With or Without Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(NSCLC)Estimated Study Start Date  :April 1, 2019Estimated Primary Completion Date